MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer

BACKGROUND: In the absence of targetable mutations or immune checkpoints, cisplatin-doublet chemotherapy remains the standard of care in non-small cell lung cancer (NSCLC). Drug resistance has however become a significant clinical challenge. Exploring a role for small non-coding microRNAs (miRNA) as...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Lung Cancer Res
Autors principals: MacDonagh, Lauren, Gallagher, Michael F., Ffrench, Brendan, Gasch, Claudia, Gray, Steven G., Reidy, Marie, Nicholson, Siobhan, Leonard, Niamh, Ryan, Ronan, Young, Vincent, O’Leary, John J., Cuffe, Sinead, Finn, Stephen P., O’Byrne, Kenneth J., Barr, Martin P.
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2021
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107736/
https://ncbi.nlm.nih.gov/pubmed/34012792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-959
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars